Cabaletta Bio
$10.879876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$10.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.28 (-2.51%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell Cabaletta Bio and other stocks, options, and ETFs commission-free!
About CABA
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA. The listed name for CABA is Cabaletta Bio, Inc. Common Stock.
CEO
Steven Nichtberger
Employees
22
Headquarters
Philadelphia, Pennsylvania
Founded
2017
Market Cap
266.41M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
118.37K
High Today
$11.44
Low Today
$10.55
Open Price
$11.22
Volume
99.85K
52 Week High
$17.86
52 Week Low
$5.51
CABA Earnings
-$0.65
-$0.43
-$0.22
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 29, Pre-Market